PRE

Prenetics Global Limited Class A Ordinary Share

20.61

USD

PRE Earnings Reports

Positive Surprise Ratio

PRE beat 6 of 13 last estimates.

46%

Next Report

Date of Next Report

Jun 10, 2026

Estimate for Q1 26 (Revenue/ EPS)

$37.50M

-$1.03

Implied change from Q4 25 (Revenue/ EPS)

+2.59%

-41.14%

Implied change from Q1 25 (Revenue/ EPS)

+116.64%

+28.75%

Prenetics Global Limited Class A Ordinary Share earnings per share and revenue

On Feb 18, 2026, PRE reported earnings of -1.75 USD per share (EPS) for Q4 25, missing the estimate of -0.34 USD, resulting in a -404.61% surprise. Revenue reached 36.56 million, compared to an expected 33.77 million, with a 8.26% difference. The market reacted with a -7.73% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 2 analysts forecast an EPS of -1.03 USD, with revenue projected to reach 37.50 million USD, implying an decrease of -41.14% EPS, and increase of 2.59% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Prenetics Global Limited Class A Ordinary Share's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Prenetics Global Limited Class A Ordinary Share reported EPS of -$1.75, missing estimates by -404.61%, and revenue of $36.56M, 8.26% above expectations.

How did the market react to Prenetics Global Limited Class A Ordinary Share's Q4 2025 earnings?

The stock price moved down -7.73%, changed from $21.74 before the earnings release to $20.06 the day after.

When is Prenetics Global Limited Class A Ordinary Share expected to report next?

The next earning report is scheduled for Jun 10, 2026.

What are the forecasts for Prenetics Global Limited Class A Ordinary Share's next earnings report?

Based on 2 analysts, Prenetics Global Limited Class A Ordinary Share is expected to report EPS of -$1.03 and revenue of $37.50M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.